Empagliflozin vs Dapagliflozin
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.
Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.
Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.
See our Terms of Use and Editorial Policy.
Empagliflozin (Jardiance) and dapagliflozin (Farxiga) are both SGLT2 inhibitors with FDA approval for type 2 diabetes, heart failure, and chronic kidney disease. They work by blocking glucose reabsorption in the kidneys, causing excess sugar to be excreted in the urine. Beyond blood sugar control, both have demonstrated remarkable cardiovascular and kidney benefits that have transformed how these drugs are prescribed.
With overlapping indications, the choice between empagliflozin and dapagliflozin often comes down to trial data nuances, insurance formulary preference, and doctor familiarity.
Empagliflozin vs Dapagliflozin: Side-by-side comparison
| Category | Empagliflozin | Dapagliflozin |
|---|---|---|
| Drug Class | SGLT2 Inhibitor | SGLT2 Inhibitor |
| Brand Name | Jardiance | Farxiga |
| Standard Dose | 10-25 mg once daily | 5-10 mg once daily |
| CV Death Reduction | Yes (EMPA-REG: 38% reduction) | Trend but not significant |
| HF Hospitalization Reduction | Yes | Yes |
| CKD Indication | Yes (EMPA-KIDNEY) | Yes (DAPA-CKD) |
| Key Trial | EMPA-REG OUTCOME | DECLARE-TIMI 58 / DAPA-HF |
Efficacy: How well does each drug work?
Both drugs effectively lower HbA1c by approximately 0.5-0.8% when added to existing diabetes therapy. For blood sugar control alone, they are considered clinically equivalent.
The landmark cardiovascular trials for each drug showed important benefits. The EMPA-REG OUTCOME trial showed empagliflozin significantly reduced cardiovascular death (by 38%) in patients with type 2 diabetes and established cardiovascular disease. The DECLARE-TIMI 58 trial showed dapagliflozin significantly reduced heart failure hospitalizations.
For heart failure specifically, both drugs are now FDA-approved for heart failure with reduced ejection fraction, regardless of diabetes status. The EMPEROR-Reduced (empagliflozin) and DAPA-HF (dapagliflozin) trials showed similar benefits. For chronic kidney disease, the DAPA-CKD and EMPA-KIDNEY trials confirmed kidney-protective effects for both drugs.
Side effects comparison
Both medications share the same class-related side effects: genital mycotic (yeast) infections (more common in women), urinary tract infections, increased urination, and risk of dehydration. Volume depletion can be a concern in elderly patients or those on diuretics.
Both drugs carry warnings for diabetic ketoacidosis (DKA), including euglycemic DKA (normal blood sugar with ketoacidosis), which is rare but dangerous. Patients should be aware of DKA symptoms: nausea, vomiting, abdominal pain, and unusual fatigue.
Neither empagliflozin nor dapagliflozin has been associated with the lower-limb amputation risk seen with canagliflozin. Their safety profiles are very similar overall, and no head-to-head safety comparison has identified meaningful differences between them.
Cost comparison
Both medications are similarly priced as branded drugs, typically $500-$600 per month at retail without insurance. Generic availability is emerging for both, which will significantly reduce costs.
Insurance formulary placement is often the primary cost differentiator. Many plans prefer one SGLT2 inhibitor over others, making one significantly cheaper in copay for a given patient. Check with your insurance to see which is preferred on your plan.
Convenience and dosing
Both drugs are taken once daily by mouth. Empagliflozin is available in 10 mg and 25 mg tablets, and dapagliflozin in 5 mg and 10 mg tablets. Neither requires dose titration based on blood sugar levels, and both can be taken with or without food at any time of day.
From a practical standpoint, there is no meaningful difference in convenience between the two drugs.
Which is right for you?
Empagliflozin and dapagliflozin are clinically very similar. For most patients, the choice will be determined by insurance coverage and formulary preference rather than clinical superiority of one over the other.
If you have established cardiovascular disease, the EMPA-REG mortality data for empagliflozin is particularly strong. If you have CKD without diabetes, both have strong kidney protection data (DAPA-CKD was published first and included non-diabetic CKD patients).
Both are excellent choices. Work with your doctor and insurance plan to determine which is most accessible and affordable for you.
Frequently asked questions
References
- [Observational] Jardiance (empagliflozin) FDA Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204629s026lbl.pdf Accessed 2026-03-01.
- [Observational] Farxiga (dapagliflozin) FDA Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202293s024lbl.pdf Accessed 2026-03-01.
- [Observational] EMPA-REG OUTCOME Trial https://pubmed.ncbi.nlm.nih.gov/26378978/ Accessed 2026-03-01.
- [Observational] DAPA-HF Trial https://pubmed.ncbi.nlm.nih.gov/31535829/ Accessed 2026-03-01.
Written and fact-checked by PrescriptionDrugs.org Editorial Team
Last updated: